Sigma Planning Corp Clovis Oncology, Inc. Transaction History

Sigma Planning Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$1.05 - $2.85 $8,032 - $21,802	7,650 Added 17.19%	52,148 $62,000
Q2 2022 Aug 11, 2022	BUY	$0.63 - $2.96 $8,190 - $38,480	13,000 Added 41.27%	44,498 $80,000
Q1 2022 Apr 20, 2022	BUY	$1.43 - $3.14 $26,096 - $57,301	18,249 Added 137.74%	31,498 $64,000
Q4 2021 Feb 02, 2022	BUY	$2.7 - $4.76 $35,772 - $63,065	13,249 New	13,249 $36,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.